Claims
- 1. A compound of the formula: ##STR12## wherein R.sup.1 and R.sup.2 each individually are hydrogen or lower alkyl optionally substituted by aryl or C.sub.3-6 -cycloalkyl;
- R.sup.4 and R.sup.5 are both hydrogen or are both halogen or one is hydrogen and the other is halogen, hydroxy, lower alkoxy, aryloxy or amino; and
- R.sup.3 is hydrogen or, where no primary or secondary amino group is present, hydrogen or alkanoyl;
- and pharmaceutically acceptable acid addition salts; with the proviso that all the groups R.sup.1 through R.sup.5 cannot simultaneously be hydrogen.
- 2. A compound of the formula: ##STR13## wherein: R.sup.1 and R.sup.2 independently are hydrogen or lower alkyl optionally substituted by C.sub.3-6 -cycloalkyl,
- R.sup.3 is hydrogen or, where R.sup.1 and R.sup.2 are both lower alkyl, R.sup.3 is hydrogen or alkanoyl, and
- two of the groups R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are halogen and the remaining two groups are hydrogen, or three of the groups R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are hydrogen and the other is halogen, heteroaryloxy, lower alkoxy or hydroxy.
- 3. The compound of claim 2 wherein R.sup.1 and R.sup.2 are both hydrogen or are both lower alkyl, R.sup.3 is hydrogen or, where R.sup.1 and R.sup.2 are both lower alkyl, R.sup.3 is hydrogen or alkanoyl, and two of the groups R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are halogen and the remaining two groups are hydrogen, or three of the groups R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are hydrogen and the remaining group is halogen, lower alkoxy or hydroxy.
- 4. The compound of claim 3 wherein said compound is rac-cis-4b-(2-dimethylamino-ethyl)-3-methoxy-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 5. The compound of claim 3 wherein said compound is rac-cis-4b-(2-amino-ethyl)-3-chloro-1-fluoro-4b,5,6,7,8, 8a,9,10-octahydro-phenanthren-8a-ol.
- 6. The compound of claim 2 wherein R.sup.1 and R.sup.2 are lower alkyl, R.sup.3 is hydrogen or alkanoyl, and all of the groups R.sup.4, and R.sup.5, R.sup.6 and R.sup.7 are hydrogen, or three of the groups R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen and the remaining group is halogen or hydroxy.
- 7. The compound of claim 6 having the formula: ##STR14## wherein all of the groups R.sup.4, and R.sup.5, R.sup.6 and R.sup.7 are hydrogen, or three of the groups R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen and the remaining group is halogen or hydroxy.
- 8. The compound of claim 7 wherein R.sup.4, R.sup.5, and R.sup.7 are hydrogen and R.sup.6 is halogen or hydroxy.
- 9. The compound of claim 8 wherein said compound is acetic acid rac-cis-4b-(2-dimethylamino-ethyl)-3-fluoro-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-yl ester.
- 10. The compound of claim 8 wherein said compound is acetic acid rac-cis-3-chloro-4b-(2-dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-yl ester.
- 11. The compound of claim 6 having the formula: ##STR15## wherein all of the groups R.sup.4, and R.sup.5, R.sup.6 and R.sup.7 are hydrogen, or three of the groups R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen and the remaining group is halogen or hydroxy.
- 12. The compound of claim 11 wherein R.sup.4, R.sup.5, and R.sup.7 are hydrogen and R.sup.6 is halogen or hydroxy.
- 13. The compound of claim 11 wherein said compound is rac-cis-4b-(2-Dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 14. The compound of claim 12 wherein said compound is rac-cis-3-Chloro-4b-(2-dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 15. The compound of claim 12 wherein said compound is (-)-cis-3-Chloro-4b-(2-dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 16. The compound of claim 12 wherein said compound is (+)-cis-3-Chloro-4b-(2-dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 17. The compound of claim 12 wherein said compound is rac-cis-4b-(2-Dimethylamino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthrene-3,8a-diol.
- 18. The compound of claim 12 wherein said compound is rac-cis-4b-(2-dimethylamino-ethyl)-3-fluoro-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 19. The compound of claim 3 having the formula: ##STR16## wherein three of the groups R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen and the remaining group is halogen or hydroxy.
- 20. The compound of claim 19 wherein the groups R.sup.4, R.sup.5, and R.sup.7 are hydrogen and the group R.sup.6 is halogen or hydroxy.
- 21. The compound of claim 20 wherein said compound is rac-cis-4b-(2-Amino-ethyl)-3-fluoro-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 22. The compound of claim 20 wherein said compound is rac-cis-4b-(2-amino-ethyl)-3-chloro-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 23. The compound of claim 20 wherein said compound is rac-cis-4b-(2-amino-ethyl)-3-bromo-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol.
- 24. The compound of claim 20 wherein said compound is rac-cis-4b-(2-amino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthrene-3,8a-diol.
- 25. The compound of claim 20 wherein said compound is (+)-cis-4b-(2-amino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthrene-3,8a-diol.
- 26. The compound of claim 20 wherein said compound is (-)-cis-4b-(2-amino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthrene-3,8a-diol.
- 27. A method for the prevention of neuronal damage due to hypoxia or ischemia in a host which comprises administering to the host an effective amount of a compound wherein the compound is rac-cis-4b-(2-amino-ethyl)-4b ,5,6,7,8,8a,9,10-octahydro-phenanthrene-8a-ol or a pharmaceutically acceptable acid addition salt thereof.
- 28. The method of claim 27 wherein the compound is administered orally and the amount is from 50-500 mg per day.
- 29. A pharmaceutical composition for the prevention of neuronal damage due to hypoxia or ischemia in a host which comprises an effective amount of rac-cis-4b-(2-amino-ethyl)-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-8a-ol or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient.
Priority Claims (1)
Number |
Date |
Country |
Kind |
123/93 |
Jan 1993 |
CHX |
|
Parent Case Info
This is a continuation of application Ser. No. 08/179,215, filed January 10, 1994, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4317910 |
Hauck et al. |
Mar 1982 |
|
5071853 |
Bigge et al. |
Dec 1991 |
|
5180736 |
Johnson et al. |
Jan 1993 |
|
5276053 |
Johnson et al. |
Jan 1994 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
388977 |
Mar 1990 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Doyle, et al., Tetrahedron Letters, 23: pp. 1889-1892 (1969). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
179215 |
Jan 1994 |
|